Ignite Creation Date:
2025-12-24 @ 2:19 PM
Ignite Modification Date:
2026-01-01 @ 4:15 PM
Study NCT ID:
NCT07228195
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-12-11
First Post:
2025-10-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SGLT2i Therapy in Islet Transplantation (SIT)
Sponsor:
University of Minnesota
Organization:
Study Overview
Official Title:
SGLT2i Therapy in Islet Transplantation (SIT)
Status:
NOT_YET_RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This pilot clinical trial is designed to gather preliminary data on the efficacy and safety of empagliflozin, a diabetes drug in the sodium-glucose cotransporter 2 inhibitor (SGLT2i) class, in islet autotransplant recipients who have partial islet function.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: